Boehringer Ingelheim Pharmaceuticals Press Release (06/28/12)
Results from a two-year study published in The Lancet showed that Trajenta (linagliptin) offered blood glucose improvements similar to those offered by the commonly prescribed sulphonylurea, glimepiride, when used to treat adult patients with type 2 diabetes who were inadequately controlled on metformin alone. The study of 1,552 patients also showed that linagliptin was associated with significantly fewer hypoglycaemic events and lead to relative weight loss of 2.7 kg compared to glimepiride. The ongoing, head-to-head outcomes trial CAROLINA is also investigating the profile of linagliptin vs. glimepiride.

Read the complete article